Patients With Kidney Cancer by Yaycioglu, O et al.
A Preoperative Prognostic Model Predicting Recurrence-free
Survival for Patients With Kidney Cancer
Ozgur Yaycioglu1,*, Saadettin Eskicorapci2, Erdem Karabulut3, Bulent Soyupak4, Cagatay Gogus5, Taner Divrik6,
Levent Turkeri7, Sertac Yazici8, Haluk Ozen8 and Society of Urooncology Study Group for Kidney Cancer
Prognosis†
1Department of Urology, Baskent University, Adana, 2Department of Urology, Pamukkale University, Denizli,
3Department of Biostatistics, Hacettepe University, Ankara, 4Department of Urology, Cukurova University, Adana,
5Department of Urology, Ankara University, Ankara, 6Department of Urology, Tepecik Hospital, Izmir, 7Department of
Urology, Marmara University, Istanbul and 8Department of Urology, Hacettepe University, Ankara, Turkey
*For reprints and all correspondence: Ozgur Yaycioglu, Baskent University School of Medicine, Department of
Urology, Adana Clinic & Research Center, Dadaloglu MH. 39 SOK. NO:6, 01250 Yuregir, Adana, Turkey.
E-mail: yaycioglu@yahoo.com
†Members of the Society of Urooncology Study Group for Kidney Cancer Prognosis are listed in the Appendix.
Received June 26, 2012; accepted October 16, 2012
Objective: To develop a preoperative prognostic model in order to predict recurrence-free
survival in patients with nonmetastatic kidney cancer.
Methods: A multi-institutional data base of 1889 patients who underwent surgical resection
between 1987 and 2007 for kidney cancer was retrospectively analyzed. Preoperative vari-
ables were defined as age, gender, presentation, size, presence of radiological lymph nodes
and clinical stage. Univariate and multivariate analyses of the variables were performed using
the Cox proportional hazards regression model. A model was developed with preoperative
variables as predictors of recurrence after nephrectomy. Internal validation was performed by
Harrell’s concordance index.
Results: The median follow-up was 23.6 months (1–222 months). During the follow-up, 258
patients (13.7%) developed cancer recurrence. The median follow-up for patients who did not
develop recurrence was 25 months. The median time from surgery to recurrence was 13
months. The 5-year freedom from recurrence probability was 78.6%. All variables except age
were associated with freedom from recurrence in multivariate analyses (P, 0.05). Age was
marginally significant in the univariate analysis. All variables were included in the predictive
model. The calculated c-index was 0.747.
Conclusions: This preoperative model utilizes easy to obtain clinical variables and predicts
the likelihood of development of recurrent disease in patients with kidney tumors.
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INTRODUCTION
Renal cell carcinoma is a heterogeneous disease with a
highly variable prognosis. Although numerous prognostic
factors have been described, no single factor has been shown
as a perfect indicator of prognosis. Outcome prediction
models also known as prognostic models combine several
prognostic factors in order to better predict the prognosis.
These models may be used by practitioners to guide treat-
ment decisions, counsel patients, select follow-up schedules
tailored to the risk of cancer progression, determine the need
for adjuvant therapy and stratify patients for clinical trials.
As far as renal cell carcinoma is considered, various
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prognostic models have been developed for both patients
with localized and metastatic diseases (1–11). Models for
localized disease can further be subcategorized as preopera-
tive and postoperative models. The preoperative models
might suffer from lack of accuracy because they do not have
the advantage of incorporating powerful prognostic variables
such as histological type and grade of tumor. An ideal pre-
operative model with very high accuracy is yet to be
described and externally validated.
The objective of this study was to develop a preoperative
prognostic model that can be used to predict recurrence-free
survival after nephrectomy in patients with renal cancer and
no sign of distant metastasis at the time of surgery. We used
data from a multi-institutional database and defined a nomo-
gram utilizing readily available clinical and radiological
parameters to achieve a practical but also accurate preopera-
tive prognostic model.
PATIENTS AND METHODS
Twenty-five institutions participated to the study. These
centers contributed data retrospectively from all patients who
underwent radical or partial nephrectomy between 1987 and
2007 for kidney tumors and had no evidence of distant me-
tastasis at the time of surgery. Patients with von
Hippel-Lindau disease and synchronous bilateral tumors
were not included in the database. A datasheet was provided
to all centers to enter the required data that were then pooled
in one single database. The final database consisted of 1889
patients.
Preoperative variables were defined as age at the time of
surgery, gender, clinical presentation, radiological size, pres-
ence of radiological lymph nodes and clinical stage. Clinical
presentation was categorized as incidental, local symptoms
or systemic symptoms. Incidental tumors were defined as
those that were detected during evaluation of an unrelated
medical condition, and the patients had no kidney tumor-
related symptoms at the time of diagnosis. Patients with
Common Terminology Criteria for Adverse Effects
(CTCAE) Grade 1 or greater symptoms (such as Grade 1
pain, urine color change or constitutional symptoms etc.)
were regarded as symptomatic. Locally symptomatic patients
were defined as those who presented with flank pain, flank or
abdominal mass or hematuria. Patients with systemic symp-
toms were defined as those who presented with fever, weight
loss, fatigue or signs and symptoms caused by paraneoplastic
disorders. Those with both local and systemic symptoms
were considered in the systemic symptoms group.
Preoperative work-up for staging varied between the centers
but mostly consisted of bone scans, blood biochemistry and
computerized tomography (CT) scans of the chest, abdomen
and pelvis. Some patients had magnetic resonance imaging
(MRI) scans of the abdomen. Cross-sectional imaging (CT
and/or MRI scans) were used to measure the radiological
size, assign clinical stage and identify the presence of
regional lymph nodes. The radiological size was defined as
the largest diameter of the tumor. The presence of regional
lymph nodes was defined as nodes .10 mm. Clinical T and
N stages were assigned according to the 2002 TNM staging
system of the American Joint Committee on Cancer (12).
The follow-up protocols varied between centers.
Generally, patients were followed up at 3–12 monthly inter-
vals by physical examination, routine laboratory evaluation,
chest X-ray, CT or ultrasonography. The time to recurrence
was defined as the interval from surgery to the first evidence
of disease recurrence.
The end points of the study were time until the detection
of kidney cancer recurrence and the time to last follow-up if
the patient was alive, or time until death if the patient died
without kidney cancer recurrence. Kidney cancer recurrence
was defined as local or metastatic cancer recurrence or de-
velopment of cancer in the opposite kidney. Outcomes were
measured in terms of disease recurrence. Patients were either
alive without metastases, dead without metastases or had
disease recurrence (local or metastatic). Patients were cen-
sored at the time of death or last follow-up without metasta-
sis. Progression-free probability was estimated using the
Kaplan–Meier method. Univariate analysis of the variables
was performed by the Cox proportional hazards regression
model. Multivariate analysis was performed with the Cox
proportional hazards regression model and 95% confidence
intervals (95% CI) were calculated on 1000 bootstrap
samples. The results of the analyses were used to model pre-
operative variables as predictors of recurrence after nephrec-
tomy. Thus, a nomogram was constructed for the probability
of recurrence-free survival. Internal validation of the model
was performed by calculating Harrell’s concordance index.
All analyses were performed using S-plus 2000 professional
software.
RESULTS
Characteristics of the 1889 patients are presented in Table 1.
The types of surgical procedures were as follows: 1655
patients open radical nephrectomy, 194 patients open partial
nephrectomy, 36 patients laparoscopic radical nephrectomy
and 4 patients laparoscopic partial nephrectomy. The smal-
lest tumor was 9 mm and the largest tumor was 300 mm in
size. Pathologic evaluations revealed clear cell carcinoma in
1431 patients (75.8%), papillary in 185 (9.8%) patients,
chromophobe in 138 (7.3%) patients. In the remaining 135
(7.1%) patients, the histological subtype was reported as col-
lecting duct carcinoma or unclassified/undetermined. The
median follow-up was 23.6 months and ranged from 1 to
222 months. During the follow-up, 258 patients (13.7%)
developed recurrent disease. The median follow-up for
patients who did not develop recurrent disease was 25
months and ranged from 1 to 222 months. The median time
from surgery to disease recurrence was 13 months and
ranged from 1 to 153 months. The 5-year freedom from
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recurrence probability for the study cohort was 78.6% (95%
CI 75.9–81.3%).
On univariate analysis, patient age, gender, mode of pres-
entation, radiological size of the renal mass, clinical tumor
stage and evidence of lymph nodes on imaging were signifi-
cant predictors of recurrence. The results of univariate and
multivariate analyses are presented in Table 2. All of the
variables except age were associated with freedom from re-
currence in multivariate analyses (P, 0.05). However, since
patient age was marginally significant in the univariate ana-
lysis, all variables including age were included in the pre-
dictive model. The nomogram constructed from the
multivariate Cox regression coefficients is shown in Fig. 1.
Harrell’s c-index developed across the 1889 patients was
0.747.
COMMENTS
Standard treatment for patients with renal cell carcinoma is
radical or partial nephrectomy. Preoperative diagnosis is
made with radiological evaluation in most of the cases and
tissue diagnosis is seldom indicated. With no pathologic
variables available, decision-making and patient counseling
before nephrectomy are based mostly on clinical variables.
An accurate tool for the prediction of prognosis would serve
well for clinical decision-making and patient counseling.
Preoperative predictive differentiation of patients is useful to
choose patients for neoadjuvant treatment trials and possibly
for neoadjuvant treatment protocols in the near future. The
prediction of prognosis with preoperative clinical variables is
also useful for patients whose pathologic variables are not
available such as those treated with needle ablative proce-
dures and morcellation of the specimen during laparoscopy.
Five preoperative prognostic models have been published
to date (Table 3) (1–5). Yaycioglu et al. reviewed data from
296 patients who underwent open nephrectomy at Johns
Hopkins Hospital and generated a prognostic model to cat-
egorize patients in low- and high-risk groups in terms of
disease recurrence according to the clinical size and mode of
presentation (1). A similar model was also developed with
data from three European institutes (2). The main limitation
of such models is that they omit individual differences in
prognosis and instead categorize patients into limited
number of risk groups. This results in clustering of patients
with varying prognosis in the same group. Accordingly,
these two models, although very easy to use, suffered low
predictive accuracies in a multi-institutional external valid-
ation study (13). The third published model is developed by
a multi-institutional study from Canada and Europe. This
model is a nomogram for the prediction of freedom from
renal cell carcinoma-specific mortality (3). Nomograms are
graphic charts that provide outcome probabilities tailored to
the individual’s characteristics and provide information for
individual patient counseling. This study had a model devel-
opment cohort and an external validation cohort, and the
nomogram prediction at 5 years was 86.8% accurate. The
fourth model is a preoperative nomogram that predicts
the 12-year probability of metastatic renal cancer after
radical or partial nephrectomy in patients with renal masses
and no concurrent evidence of metastasis (4). It was based
on data from Memorial Sloan-Kettering Cancer Center and
Mayo Clinic. This model was internally validated with a
bootstrapping technique and the resultant concordance index
was 0.8. The fifth preoperative model was reported by
authors from Japan. It is a preoperative nomogram based on
the TNM classification and predicts cause-specific survival
in patients with renal cell carcinoma (5). This study utilizes
only variables from TNM classification, and some groups
have very limited number of patients. Internal validation of
200 bootstrap samples produced a concordance index of 0.81.
The models by Raj et al. and Kanao et al. have not yet been
externally validated. Models by Karakiewicz et al. and Kanao
et al. include patients with and without metastasis. As meta-
static renal cell carcinoma has a much worse prognosis com-
pared with localized disease and the rationale for surgery in
patients with and without metastasis is quite different, it is
Table 1. Patient characteristics
Total number of patients 1889
Gender
Male 1178 (62.4)
Female 711 (37.6)
Mean age+SD at diagnosis (years) 56.7+12.4
Presentation
Incidental 821 (43.5)
Local symptoms 821 (43.5)
Systemic symptoms 247 (13.1)
Mean tumor size+SD (mm) 67.1+33.6
Clinical T stage (TNM 2002)
T1a 290 (15.4)
T1b 775 (41)
T2 400 (21.2)
T3a 249 (13.2)
T3b 91 (4.8)
T4 84 (4.4)
Presence of radiological lymph nodes
No 1723 (91.2)
Yes 166 (8.8)
Disease recurrence
No 1631 (86.3)
Yes 258 (13.7)
SD, standard deviation; numbers in parentheses are percentages.
Jpn J Clin Oncol 2013;43(1) 65
D
ow
nloaded from
 https://academ
ic.oup.com
/jjco/article-abstract/43/1/63/885563 by Pam
ukkale Ü
niversitesi user on 12 M
arch 2020
controversial to pool patients with and without metastatic
disease in a single cohort. There are already predictive models
widely in use for patients with metastasis (11).
There are several postoperative models that predict clinical
outcomes based on clinical and pathologic data (6–10). It
has been shown that models that incorporate pathological
data perform better than preoperative models. The discrimin-
ating ability of four prognostic models was compared using
an independent dataset containing more than 2404 patients
from six European centers (13). As previously mentioned,
two of these were preoperative Yaycioglu and Cindolo
models, and the other two were postoperative Kattan and
UISS models (1,2,6,7). The Kattan nomogram was consist-
ently the most accurate model with a concordance index of
0.807 for recurrence-free survival followed by the UISS
model. On the other hand, the same Kattan nomogram
showed low predictive accuracy in a sample of 565 French
patients with a concordance index of only 0.607 (14). The
significance of this variation in different datasets is not very
clear because there is no threshold for concordance index to
label a model as clinically useful or not (15). Although
factors such as differences in the definition of variables in
different datasets may result in variations in the accuracy of
a certain model (methodologic and spectrum transportabil-
ity), it is also possible that a model that works well for a
specific patient population may not necessarily be the best
model for other patient populations (geographic transport-
ability) (16).
The prognostic variables that make our nomogram are
age, sex, mode of presentation, tumor size, T stage and pres-
ence of lymph nodes. All of these variables have been
shown as important prognostic indicators in previous studies
(17–26). These variables are also easily available and
reproducible, which makes the nomogram easy to be used in
real-life clinical practice. However, some points should be
mentioned. Categorizing patients in terms of their symptoms
may at times be complex, especially when one has to differ-
entiate between local and systemic symptoms on a retro-
spective analysis. Therefore, we categorized all patients with
Table 2. Univariate and multivariate Cox regression model for the prediction of recurrence-free survival after nephrectomy
Variables Univariate Multivariate
HR (95% CI) P value* HR (95% CI) P value*
Patient age 1.01 (1.002–1.021) 0.017 1.01 (0.998–1.020) 0.155
Gender 0.64 (0.479–0.820) 0.002 0.64 (0.472–0.840) 0.002
Presentation
Incidental 1.00 0.000 1.00 0.000
Local symptoms 1.98 (1.496–2.643) 0.001 1.51 (1.116–2.069) 0.010
Systemic symptoms 4.10 (2.933–5.689) 0.001 2.35 (1.632–3.364) 0.001
Radiological size 1.02 (1.014–1.020) 0.001 1.01 (1.004–1.012) 0.001
Clinical stage
T1a 1.00 0.000 1.00 0.000
T1b 1.63 (0.913–3.333) 0.113 1.24 (0.690–2.626) 0.470
T2 3.85 (2.267–7.813) 0.001 1.74 (0.944–3.984) 0.111
T3a 4.33 (2.524–8.997) 0.001 1.88 (0.967–4.199) 0.074
T3b 10.56 (5.583–22.232) 0.001 3.88 (1.982–8.929) 0.001
T4 9.85 (4.912–21.707) 0.001 2.27 (1.084–5.983) 0.046
Radiological lymph nodes 4.99 (3.670–6.749) 0.001 2.47 (1.692–3.617) 0.001
HR, hazard ratio; CI, confidence interval; CS, clinical stage.
*P value calculated on 1000 bootstrap samples.
Figure 1. Preoperative nomogram predicting probability of recurrence-free
survival at 5 years.
66 Preoperative nomogram for recurrence-free survival in renal cancer
D
ow
nloaded from
 https://academ
ic.oup.com
/jjco/article-abstract/43/1/63/885563 by Pam
ukkale Ü
niversitesi user on 12 M
arch 2020
any systemic complaints into systemic group, even if their
primary complaint was local symptoms. However, inter-
observer variability is always a possibility. For tumor size,
we chose to use the largest diameter on CT or MRI. It can
be argued that calculation of tumor volume represents the
tumor burden more accurately. However, since a largest
tumor diameter is easier to calculate and leaves less space
for inter-observer variability, we preferred to use it instead.
Radiological determination of the exact number of involved
lymph nodes may also be problematic. Therefore, we chose
to categorize the patients as those with and those without
lymph node involvement. There are debates going on over
TNM classification and the definition and subcategorization
of T stage, which is constantly evolving. It is probable that
further refinements on the definition of T stage may be
incorporated to the nomogram. However, this subject is to be
investigated in the future external validation studies. The
limitations of the study are its retrospective nature, relatively
short follow-up and the lack of standardized follow-up proto-
col. On the other hand, the multi-center nature of the study
and the number of the enrolled patients are positive aspects.
The internal validation of the model resulted in a concord-
ance index of 0.747. This c-index shows that the model has
a good accuracy but it is not perfect. The model is yet to be
externally validated. There is still room for improvement of
the predictive ability of preoperative models. There are
efforts to improve the predictive ability of the published
postoperative models by integrating molecular markers to
these models (27). Improvements on the accuracy of needle
biopsy of kidney tumors may allow incorporation of histo-
logic characteristics and tissue molecular markers to the pre-
operative models as well (28).
CONCLUSIONS
This model predicts the likelihood of the development of
cancer recurrence in patients with kidney tumors before neph-
rectomy. It is a user-friendly nomogram and utilizes easy-
to-obtain clinical variables. The model is useful to counsel
patients before surgery. It can be used as a tool to enroll
patients in clinical trials and to choose which patients would be
served best by possible neoadjuvant treatments in the future.
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